Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) PT at $85.67

Structure Therapeutics Inc. (NASDAQ:GPCR) has been assigned an average rating of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $85.67.

A number of equities research analysts recently weighed in on GPCR shares. HC Wainwright started coverage on shares of Structure Therapeutics in a report on Wednesday, December 4th. They issued a “buy” rating and a $80.00 price objective for the company. Morgan Stanley began coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd.

Hedge Funds Weigh In On Structure Therapeutics

Hedge funds have recently modified their holdings of the stock. Sandia Investment Management LP acquired a new stake in shares of Structure Therapeutics during the second quarter valued at approximately $39,000. Assetmark Inc. grew its position in Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after purchasing an additional 719 shares in the last quarter. Quarry LP acquired a new stake in Structure Therapeutics during the 2nd quarter valued at $79,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Structure Therapeutics by 60.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock valued at $158,000 after purchasing an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC acquired a new stake in shares of Structure Therapeutics in the third quarter worth $202,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Stock Performance

Shares of GPCR stock opened at $31.48 on Friday. Structure Therapeutics has a 1 year low of $26.61 and a 1 year high of $62.74. The firm has a market capitalization of $1.80 billion, a PE ratio of -42.54 and a beta of -3.41. The stock has a fifty day moving average of $35.95 and a two-hundred day moving average of $39.17.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.